期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

罗格列酮对糖尿病大鼠血清中MCP-1水平的影响

The effect of rosiglitazone on the blood serum Monocyte chemoattractant protein-1 levels of diabetic rats
下载PDF
导出
摘要 目的观察罗格列酮对糖尿病大鼠血中MCP-1水平的影响,以了解其对糖尿病大血管病变的保护作用。方法建立糖尿病大鼠模型,分为正常对照组(A)、糖尿病组(B组)、罗格列酮治疗组(C组)。糖尿病大鼠模型建立一周后,C组以罗格列酮(5 mg.kg-1.d-1)灌胃,A组和B组灌以相应量的生理盐水,检测各组每周血糖、检测第8周血清中MCP-1水平。结果血糖水平B组和C组相近,均显著高于A组(P<0.01),第8周A、B、C三组血清中MCP-1分别为3.817±0.046 pg/ml、4.150±0.064 pg/ml、3.971±0.113 pg/ml,B组和C组血中MCP-1水平均显著高于A组(P<0.01),其中C组较B组明显减少(P<0.01)。结论罗格列酮在降低血糖的同时还有抗炎作用,对糖尿病大血管病变有一定的保护作用。 Objective To observe the effect of rosiglitazone on the blood serum monocyte chemoattractant protein- 1 （ MCP- 1 ） levels,and find its protective effects on macroangiopathy.Methods 24 Wistar rots were randomly assigned to normal control（group A） group, diabetic（group B）group and roslglitazone treatment（group C） group. Rats in group C were treated with rosiglitazone（5 mg· kg^-1· d ^- 1 ） one week after the establistmaent of diabetic model, group A and B were treated with corresponding sodium chloride. Blood glucose levels were testsd weekly,blood MCP-1 levels were tested at the 8th week. Results At the 2nd,4th and 8th week,blood glu- cose levels in group B were similar to those of group C, which were much higher than those of group A. Blood MCP- 1 levels in group B and group C were higher than that of group A, and blood MCP-1 levels in group C were lower than that of group B. Conclusion Rosiglitazone has the effect of antiinflammation, which may play some protection against the progress of atherogenesis in diabetic rats.
作者 林杨 叶山东 陈燕 范爱红 杨光伟 李秀财
机构地区 安徽医科大学附属省立医院安徽省立医院内分泌科
出处 《中国实验诊断学》 2007年第12期1581-1583,共3页 Chinese Journal of Laboratory Diagnosis
关键词 罗格列酮 糖尿病 大血管病变 MCP-1 rosiglitazone diabetes mellitus macroangiopathy MCP- 1
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献12

  • 1Kamei N, Tobe K, Suzuki R, et al, Overexpression of monceyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance [J] .J Biol Chem,2006,2.81 (36) :26602.
  • 2Han KH, Ryu J, Hong KH, et al. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-medlated monocyte recruitment in vivo [J]. Circulation, 2005,111(11):1439.
  • 3Lee S, Kim B, Sik Y, et al. Hight glucose induces MCP-1 expression partly via tyrosine kinase-AP-1 pathway in peritoneal mesothelial cells[J], Kidney Int, 2001,60 ( 1 ) : 55.
  • 4Ehlermann P, Eggers K, Bierhaus A, et al. Increased proinflammato ryendothelial response to S100A8/A9 after preactivation through advanced glycation end products[J]. Cardiovasc diabetol,2006,5(6) : 1.
  • 5Zhan Y, Brown C, Maynard E, et al. Ets-1 is a critical regulator of AngⅡ- mediated vascular inflammation and remodeling[J]. J Clin Invest, 2005, 115(9) :2508.
  • 6Libby P, Sukhova G, Lee RT, et al. Cytokines regulate vascular functions related to stability of the atherosclerotic plaquel [J ]. J Cardiovasc. Pharmacol, 1995,25(12) :9.
  • 7朱大龙.炎症与2型糖尿病[J].中国糖尿病杂志,2006,14(1):73-74. 被引量：58
  • 8Wang G, Wei J, Guan Y, et al. Peroxisome proliferator-activated receptor- gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary, artery disease after coronary angioplasty[J]. Metabolism, 2005,54 (5) : 590.
  • 9Yue T1 TL, Chert J, Bao W, et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor- γ agonist rosiglitazone[ J]. Circulation,2001,104(21 ) : 2588.
  • 10Tsuchida A, Yamauchi T, Takekawa S, et al. Peroxisome prolierator - activated receptor (PPAR) alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination [J]. Diabetes, 2005,54(12) : 3358.

二级参考文献21

  • 1Pickup JC,Frcpath D.Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes.Diabetes care,2004,27:813-823.
  • 2Crook MA,Tutt P,Simpson H,et al.Serum sialic acid and acute phase proteins in type 1 and 2 diabetes.Clin Chim Acta,1993,219:131-138.
  • 3Pickup JC,Chusney GC,Thomas SM,et al.Plasma interleukin-6,tumor necrosis factor alpha and blood cytokine production in types 2 diabetes.Life Sci,2000,67:291-300.
  • 4Leinonen E,Hurt-Camejo E,Wiklund O,et al.Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes.Atherosclerosis,2003,166:387-394.
  • 5schmidt MI,Duncan BB,Sharrett AR,et al.Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study):a cohort study.Lancet,1999,353:1649-1652.
  • 6Freeman DJ,Norrie J,Caslake MJ,et al.C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study.Diabetes,2002,51:1596-1600.
  • 7Pradhan AD,Manson JE,Rifai N,et al.C-reactive protein,interleukin 6,and risk of developing type 2diabetes mellitus.JAMA,2001,286:327-334.
  • 8Festa A,D'Agostino R,Tracey RP,et al.Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes:the Insulin Resistance Atherosclerosis Study.Diabetes,2002,51:1131-1137.
  • 9Yuan M,Konstantopoulos N,Lee JS,et al.Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of IKKβ.Science,2001,293:1673-1677.
  • 10Hundal R S,Petersen K F,Mayerson A B,et al.Mechanism by which high-dose Aspirin improves glucose metabolism in type 2 diabetes.J Clin Invest,2002,109:1321-1326.

共引文献57

中国实验诊断学
2007年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部